ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
ADMA Biologics (ADMA) Prices 11.25M Common Stock Offering at $4/Share
May 17, 2019 7:13 AM EDTADMA Biologics, Inc. (Nasdaq: ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 11,250,000 shares of its common stock at a public offering price of $4.00 per share,... More
